Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Grande

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Blood|August 13, 2017
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphomaAntonio Salar, Eva Domingo-Domenech, Carlos Panizo, et al.
British Journal of Haematology|November 17, 2015
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximabMaribel Forero-Castro, Cristina Robledo, Eva Lumbreras, et al.
The Lancet. Haematology|April 1, 2016
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trialAntonio Salar, Eva Domingo-Domenech, Carlos Panizo, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 7, 2015
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI studyCarlos Panizo, Anny Jaramillo Rodríguez, Gonzalo Gutiérrez, et al.
Blood Cancer Journal|July 10, 2024
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, et al.
Cancer Medicine|January 25, 2021
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO groupJuan-Manuel Sancho, Rubén Fernández-Alvarez, Francisco Gual-Capllonch, et al.
British Journal of Haematology|January 25, 2003
Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea phase II trialJuan José Lahuerta, Carlos Grande, Joaquín Martínez-Lopez, et al.
Journal of Clinical Medicine|March 10, 2022
Cryoballoon Ablation for Persistent and Paroxysmal Atrial Fibrillation: Procedural Differences and Results from the Spanish Registry (RECABA)Ermengol Vallès, Jesús Jiménez, Julio Martí-Almor, et al.
Blood|July 12, 2013
HLA specificities are related to development and prognosis of diffuse large B-cell lymphomaMiguel Alcoceba, Elena Sebastián, Luis Marín, et al.
Haematologica|July 29, 2010
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyJuan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Blood|August 13, 2017
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphomaAntonio Salar, Eva Domingo-Domenech, Carlos Panizo, et al.
British Journal of Haematology|November 17, 2015
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximabMaribel Forero-Castro, Cristina Robledo, Eva Lumbreras, et al.
The Lancet. Haematology|April 1, 2016
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trialAntonio Salar, Eva Domingo-Domenech, Carlos Panizo, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 7, 2015
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI studyCarlos Panizo, Anny Jaramillo Rodríguez, Gonzalo Gutiérrez, et al.
Blood Cancer Journal|July 10, 2024
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, et al.
Cancer Medicine|January 25, 2021
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO groupJuan-Manuel Sancho, Rubén Fernández-Alvarez, Francisco Gual-Capllonch, et al.
British Journal of Haematology|January 25, 2003
Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea phase II trialJuan José Lahuerta, Carlos Grande, Joaquín Martínez-Lopez, et al.
Journal of Clinical Medicine|March 10, 2022
Cryoballoon Ablation for Persistent and Paroxysmal Atrial Fibrillation: Procedural Differences and Results from the Spanish Registry (RECABA)Ermengol Vallès, Jesús Jiménez, Julio Martí-Almor, et al.
Blood|July 12, 2013
HLA specificities are related to development and prognosis of diffuse large B-cell lymphomaMiguel Alcoceba, Elena Sebastián, Luis Marín, et al.
Haematologica|July 29, 2010
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyJuan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, et al.
Pageof 10